NEW YORK--(BUSINESS WIRE)--PESG Research releases new market update: Silexion Therapeutics (NASDAQ: SLXN)* continues to strengthen its position in the precision oncology landscape with breakthrough ...

Grand Cayman, Cayman Islands, March 05, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA ...

The Trump administration has frozen $108 million in federal funding for Duke Health, according to a senior administration official, after asserting a day earlier it was investigating “systemic racial ...

A research team has investigated a new combination therapy against cancer. This therapy employs systemic administration of the tissue hormone interferon-I combined with local application of Imiquimod.

The TULIP-SC trial evaluated the efficacy and safety of the subcutaneous administration of SAPHNELO compared to placebo in participants with moderately to severely active, autoantibody-positive SLE, ...

Colorectal-Specific Radiation Dose and Chemotherapy Risk for Subsequent Colorectal Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study (CCSS) Report We identified patients ...